Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Supernus Pharm
(NQ:
SUPN
)
28.11
+0.53 (+1.92%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 4, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
353,259
Open
27.65
Bid (Size)
21.07 (4)
Ask (Size)
28.35 (2)
Prev. Close
27.58
Today's Range
27.59 - 28.30
52wk Range
21.99 - 42.09
Shares Outstanding
53,145,884
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Supernus Pharmaceuticals: Q3 Earnings Insights
November 08, 2023
Via
Benzinga
Supernus Announces Third Quarter 2023 Financial Results
November 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
-24.98%
-24.98%
1 Month
+14.83%
+14.83%
3 Month
-11.49%
-11.49%
6 Month
-16.54%
-16.54%
1 Year
-21.06%
-21.06%
More News
Read More
Earnings Scheduled For November 8, 2023
November 08, 2023
Via
Benzinga
Supernus to Participate in the Jefferies London Healthcare Conference
November 07, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
November 02, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
October 25, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
October 16, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
October 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
September 27, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
October 02, 2023
Via
Benzinga
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
September 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
September 21, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 19, 2023
Via
Benzinga
Supernus to Participate in the Wells Fargo Healthcare Conference
August 31, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
September 15, 2023
Via
Benzinga
Bethany L. Sensenig Joins Supernus’ Board of Directors
August 21, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Second Quarter 2023 Financial Results
August 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023
July 24, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy
June 10, 2023
Via
The Motley Fool
Market Mixes It Up With A Broad Rally
June 05, 2023
Via
Talk Markets
Supernus to Participate in the Jefferies Healthcare Conference
May 31, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Time To Play Small Cap Life Science Stocks
May 15, 2023
Via
Talk Markets
Supernus Announces First Quarter 2023 Financial Results
May 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Something Happened In Biotech Last Week
May 08, 2023
Via
Talk Markets
Earnings Scheduled For May 9, 2023
May 09, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.